Banknote Ban Boosts Business At India E-Pharmacy Start-Ups
Executive Summary
Other retailers may be feeling the pain, but India’s nascent e-pharmacy sector says business is better than ever since the country’s prime minister outlawed 86% of the cash in circulation to address tax avoidance.
You may also be interested in...
India Pharma 2017: 3Cs And D (Disruption)?
2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.
India Pharma 2017: 3Cs And D (Disruption)?
2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.
Will 'Businessman' Trump See The Value In Indian Generics?
The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.